Advances in research on pharmacotherapy of sarcopenia

Feike, Yang; Liu, Zhijie; Chen, Wei

doi:10.1002/agm2.12168

Cited by 35 publications

(32 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, diverse strategies in designing monoclonal antibodies against MSTN have shown a significant increase in muscle mass and moderate improvement in muscle function in clinical trials—such as the case of landogrozumab. Other evaluations in individuals with sarcopenia are currently underway [ 74 , 75 ]. For example, another MSTN inhibitor, trevogrumab, enhances muscle mass and function in young and old mice.…”

Section: Other Therapeutic Approaches For Sarcopeniamentioning

confidence: 99%

“…For example, another MSTN inhibitor, trevogrumab, enhances muscle mass and function in young and old mice. Meanwhile, others (Stamulumab, Domagrozumab, a novel anti-myostatin peptide PINTA-745, and an anti-myostatin adnectin RG6206) increase muscle mass but fail to improve physical strength in clinical trials [ 75 ].…”

Section: Other Therapeutic Approaches For Sarcopeniamentioning

confidence: 99%

See 1 more Smart Citation

Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update

Jiménez-Gutiérrez

Martínez-Gómez

Martínez-Armenta

et al. 2022

Cells

View full text Add to dashboard Cite

Sarcopenia is generally an age-related condition that directly impacts the quality of life. It is also related to chronic diseases such as metabolic dysfunction associated with diabetes and obesity. This means that everyone will be vulnerable to sarcopenia at some point in their life. Research to find the precise molecular mechanisms implicated in this condition can increase knowledge for the better prevention, diagnosis, and treatment of sarcopenia. Our work gathered the most recent research regarding inflammation in sarcopenia and new therapeutic agents proposed to target its consequences in pyroptosis and cellular senescence. Finally, we compared dual X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and ultrasound (US) as imaging techniques to diagnose and follow up on sarcopenia, indicating their respective advantages and disadvantages. Our goal is for the scientific evidence presented here to help guide future research to understand the molecular mechanisms involved in sarcopenia, new treatment strategies, and their translation into clinical practice.

show abstract

Section: Other Therapeutic Approaches For Sarcopeniamentioning

confidence: 99%

Section: Other Therapeutic Approaches For Sarcopeniamentioning

confidence: 99%

Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update

Jiménez-Gutiérrez

Martínez-Gómez

Martínez-Armenta

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…Next‐generation therapies targeting molecular mechanisms and signaling pathways involved in sarcopenia and myoseatosis are being intensively investigated among others in geriatric cohorts 45 . Some of these targeted agents have shown a great potential in clinical trials, however, their effect is yet to be explored in LD/LT (Table 3, Table S5, see also Supplementary Digital Content 2 “Next generation targeted therapies”).…”

Section: Interventional Strategiesmentioning

confidence: 99%

Body composition and the skeletal muscle compartment in liver transplantation: Turning challenges into opportunities

Reichelt

Pratschke

Engelmann

et al. 2022

American Journal of Transplantation

View full text Add to dashboard Cite

Frailty, nutritional status, and body composition are increasingly under the spotlight of interest in various clinical scenarios including liver transplantation. To address the rapidly accumulating evidence in this field, recent European and North American practice guidelines have clearly underlined the clinical importance of nutritional status and body composition with adopting their assessment in patients with liver disease and in transplant candidates into their recommendations. While earlier reports, and therefore present guidelines, were focusing predominantly on quantitative alterations of the skeletal muscle mass (sarcopenia), recent studies have identified qualitative alterations such as intramuscular fat accumulation (myosteatosis) and sarcopenic obesity as emerging risk factors for poor clinical outcomes. In this review, the role of body composition in the context of liver transplantation will be discussed with a focus on the skeletal muscle compartment. A brief overview of current assessment modalities including their limitations, diagnostic challenges, prognostic significance, and pathophysiology are included. Possibilities to incorporate body composition parameters into clinical decision making are discussed. In addition, novel trends and remaining challenges in the therapeutic targeting of body composition and the skeletal muscle compartment are highlighted.

show abstract

“…In addition to the classical immunosuppressive treatment, specifically targeting dysfunctional muscle regeneration is an additional therapeutic strategy in IIM to regain muscle function. Among several approaches, such as selective androgen regulators (testosterone) or ghrelin and its mimetics [ 33 ], drugs targeting myostatin signaling have been of major interest recently in the NMD field [ 34 ]. Myostatin, a member of the transforming growth factor-β superfamily and also known as growth and differentiation factor 8 (GDF-8), is a negative regulator of muscle growth and strength by binding to and activating the receptor complex activin type II (ActRII)/Alk 4/5 (type I receptor) on skeletal muscle [ 35 , 36 , 37 ].…”

Section: Introductionmentioning

confidence: 99%

The Evolution of Complex Muscle Cell In Vitro Models to Study Pathomechanisms and Drug Development of Neuromuscular Disease

Zschüntzsch¹,

Meyer²,

Shahriyari

et al. 2022

Cells

View full text Add to dashboard Cite

Many neuromuscular disease entities possess a significant disease burden and therapeutic options remain limited. Innovative human preclinical models may help to uncover relevant disease mechanisms and enhance the translation of therapeutic findings to strengthen neuromuscular disease precision medicine. By concentrating on idiopathic inflammatory muscle disorders, we summarize the recent evolution of the novel in vitro models to study disease mechanisms and therapeutic strategies. A particular focus is laid on the integration and simulation of multicellular interactions of muscle tissue in disease phenotypes in vitro. Finally, the requirements of a neuromuscular disease drug development workflow are discussed with a particular emphasis on cell sources, co-culture systems (including organoids), functionality, and throughput.

show abstract

Advances in research on pharmacotherapy of sarcopenia

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 35 publications

References 84 publications

Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update

Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update

Body composition and the skeletal muscle compartment in liver transplantation: Turning challenges into opportunities

The Evolution of Complex Muscle Cell In Vitro Models to Study Pathomechanisms and Drug Development of Neuromuscular Disease

Contact Info

Product

Resources

About